Vysali Pharmaceuticals Ltd
₹
None%
- close price
About
[
edit about
]
[
add key points
]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE -2.05 %
- ROE %
- Face Value ₹
Pros
- Company has reduced debt.
- Company's working capital requirements have reduced from 205 days to 147 days
Cons
- Company has low interest coverage ratio.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2006 | Jun 2007 15m | |
|---|---|---|
| 5 | 10 | |
| 10 | 23 | |
| Operating Profit | -5 | -13 |
| OPM % | -104% | -134% |
| 1 | 26 | |
| Interest | 0 | 0 |
| Depreciation | 0 | 0 |
| Profit before tax | -5 | 12 |
| Tax % | 0% | 0% |
| -5 | 12 | |
| EPS in Rs | ||
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 96% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 88% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2006 | Jun 2007 | |
|---|---|---|
| Equity Capital | 5 | 5 |
| Reserves | -19 | 6 |
| 21 | 10 | |
| 5 | 5 | |
| Total Liabilities | 12 | 27 |
| 4 | 17 | |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| 8 | 10 | |
| Total Assets | 12 | 27 |
Cash Flows
Figures in Rs. Crores
| Mar 2006 | Jun 2007 | |
|---|---|---|
| 12 | ||
| -0 | ||
| -11 | ||
| Net Cash Flow | 1 |
Ratios
Figures in Rs. Crores
| Mar 2006 | Jun 2007 | |
|---|---|---|
| Debtor Days | 62 | 71 |
| Inventory Days | 565 | 377 |
| Days Payable | 130 | 108 |
| Cash Conversion Cycle | 497 | 340 |
| Working Capital Days | 263 | 147 |
| ROCE % | -2% |
Documents
Announcements
No data available.
Annual reports
No data available.